1 We investigated the mechanisms underlying the changes in vascular contractile responsiveness induced by chronic treatment with insulin in controls and established streptozotocin (STZ)-induced diabetic rats. 2 The aortic contractile response to noradrenaline (NA) showed no significant difference between controls and diabetics, but it was significantly greater in insulin-treated diabetic rats than in the other groups. To investigate the mechanism, we examined the changes in NA-induced contractility following treatment with insulin and insulin-like growth factor-1 (IGF-1) in organ-cultured control and diabetic aortas. 3 The contractile response to NA in organ-cultured diabetic rat aortas treated with insulin (500 ng ml À1 , 16 h) or IGF-1 (20 ng ml
Diabetes mellitus is an important risk factor for increased blood pressure and the development of atherosclerosis (Cohen, 1995; Feener & King, 1997; Kirpichnikov & Sowers, 2001; Eckel et al., 2002) . Although the elevation of the plasma insulin level has long been thought to contribute to the pathogenesis of these conditions in diabetes (Standly et al., 1993; Hall et al., 1995; Reaven, 1995; Abe et al., 1998) , it is uncertain how the hyperinsulinemia seen in diabetes might contribute to the pathogenesis of hypertension. Since a high plasma concentration of insulin reportedly leads to an increased firing rate in sympathetic nerves and to enhanced noradrenaline (NA) release, this may result in an increase in blood pressure (Gans et al., 1991; Tack et al., 1996) . One of the possibilities raised by in vitro studies is that hyperinsulinemia may result in an increased sensitivity of blood vessels to vasoconstrictors such as angiotensin II or catecholamines (Gans et al., 1991; Townsend et al., 1992; Hall et al., 1995) . Although both insulin and insulin-like growth factor 1 (IGF-1) reportedly increase a 1 -adrenoceptor expression via activated PI3-kinase/tyrosine protein kinase in rat vascular smooth muscle cells (Hu et al., 1996) , there is evidence that the high insulin levels found in patients with insulinomas do not cause hypertension and atherosclerosis (Hall et al., 1995) . We have demonstrated that high insulin administration does not enhance the NA-induced aortic contraction or the expression of the a 1 -adrenoceptor in control rats, although it does in established diabetic rats (which also showed increased blood pressure) (Kobayashi & Kamata, 1999) . Thus, insulin alone seems not to be sufficient to cause an increase in NA-induced contractions and blood pressure. We postulate that the mechanism underlying the insulin-induced enhancement of such contractile responses in the aorta in established diabetes does not operate in the control aorta.
Although arterial smooth muscle cells express both insulin receptors and IGF-1 receptors (Pfeifle & Ditschuneit, 1983; King et al., 1985) , recent reports suggest that the atherogenic effects of insulin may be mediated primarily via a crossreaction with the IGF-1 receptor (Bornfeldt et al., 1992; De Vries et al., 1992; Warren et al., 1996; Walker et al., 1999) IGF-1, a homologue of insulin that shares many signaling components and cellular responses with insulin itself (Blakesley et al., 1996) , has been shown to affect smooth muscle cell migration and proliferation (Bornfeldt et al., 1992; Dubey et al., 1993; Duan et al., 2000) , while chronic overexpression of IGF-1 in transgenic mice results in enhanced aortic contractility (Zhao et al., 2001) . The availability of IGF-1 in the circulation and in the tissues is regulated by seven binding proteins, IGF-binding protein-1 (IGFBP-1) through IGFBP-7 (Oh et al., 1996; Bayes-Genis et al., 2000) . There is no clear understanding of the individual functions that these may serve in vivo, particularly as most cells (smooth muscle cells being typical) secrete several IGFBPs that share at least some functional properties. Vascular smooth muscle cells are known to secrete IGFBP-2, IGFBP-4, IGFBP-5, and IGFBP-6, and these seem to modulate the action of IGF at the cellular level by regulating its availability to the IGF-1 receptor (although the function of IGFBP-6 is not yet certain). IGFBP-2 and IGFBP-4 inhibit IGF-stimulated migration in vascular smooth muscle cells by preventing IGF-1 from interacting with its receptor (Duan & Clemmons, 1998; Bayes-Genis et al., 2000) . In contrast, IGFBP-5 has been shown to have a stimulatory effect on IGF-1 in vascular smooth muscle cells (Imai et al., 1997; Duan & Clemmons, 1998) . The relationship between the IGF system and the complications associated with diabetes is particularly apparent for retinopathy, nephropathy, and neuropathy (Raz et al., 1998; Smith et al., 1999; Gerhardinger et al., 2001 ), but it is less apparent for macrovascular disease. Recently, IGF-1 and its receptor have been shown to be highly expressed both in atherosclerotic lesions and in hypertension (Grant et al., 1994; Raisanen-Sokolowski et al., 1994; Polanco et al., 1995) . Furthermore, we demonstrated that the concentration-dependent relaxations induced by IGF-1 and insulin were greater in aortas from STZ-induced diabetic rats than in the controls, although the acetylcholine (ACh)-induced relaxation was impaired. This is indirect supporting evidence for enhanced activities of the IGF-1 system in the diabetic aorta (Kobayashi & Kamata, 2002) .
Regulation of IGF-1 may be one of the several factors contributing to diabetic complications. Little is known about the involvement of the IGF-1 receptor or IGFBPs in the macrovascular disease associated with diabetes mellitus. The aim of the present study was to investigate the link between the enhanced vascular contractility associated with hyperinsulinemia in established diabetes and the IGF-1 signal system.
Methods

Animals and experimental design
Male Wistar rats, 8 weeks old and 220 -300 g in weight, received a single injection via the tail vein 65 mg kg À1 of STZ dissolved in citrate buffer. Age-matched control rats were injected with the buffer alone. Food and water were given ad libitum. This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals adopted by the Committee on the Care and Use of Laboratory Animals of Hoshi University (which is accredited by the Ministry of Education, Science, Sports and Culture, Japan).
Insulin administration
The STZ-induced diabetic rats (8 weeks after the STZ injection) and age-matched controls were treated with insulin (30 U kg À1 day
À1
) by way of osmotic mini-pumps (2ML2; Alzet, Palo Alto, CA, U.S.A.) for 2 weeks. At 10 weeks after the STZ injection, the rats were killed by decapitation under ether anesthesia.
Measurement of plasma cholesterol, LDL, and glucose
At 10 weeks after the STZ injection, plasma total cholesterol and triglycerides were determined using a commercially available enzyme kit (Wako Chemical Company, Osaka, Japan). High-density lipoprotein (HDL) cholesterol was measured following phosphotungstic-MgCl 2 precipitation of apolipoprotein B containing very-low-density lipoprotein (VLDL) and LDL (Wako Chemical Company, Osaka, Japan) (Kobayashi & Kamata, 1999; Kanie & Kamata, 2002 ).
Measurement of isometric force
As mentioned above, rats were anesthetized with diethyl ether and killed by decapitation 10 weeks after treatment with STZ or buffer. The aorta (cut into helical strips) was placed in a bath containing 10 ml modified Krebs -Henseleit solution (KHS; bubbled with 95% O 2 plus 5% CO 2 , and kept at 371C), and one end of each strip was connected to a tissue holder and the other to a force -displacement transducer, as previously described (Kobayashi & Kamata, 1999; Kobayashi et al., 2000; Kanie & Kamata, 2002) . In some preparations, the endothelium was removed by rubbing the intimal surface with a cotton swab, successful removal being functionally confirmed by the absence of a relaxation to 10 À5 M ACh. For the contraction studies, NA (10 À9 -10 À5 M), isotonic high K þ (10 -80 mM), or angiotensin II (10 À9 -10 À6 M) was added cumulatively to the bath until a maximal response was achieved. After the addition of sufficient aliquots of the agonist to produce the chosen concentration, a plateau response was allowed to develop before the addition of the next dose of the same agonist. A given strip was exposed to only one agonist.
Organ-culture procedure
The aorta was cleaned of loosely adhering fat and connective tissue, then cut into helical strips 3 mm in width and 20 mm in length. Strips were then placed in 5 ml of serum-free Leibovitz's L-15 medium supplemented with 1% penicillinstreptomycin and 10 À5 M NA. Some strips were placed in a similar solution containing 500 ng ml À1 insulin or 20 ng ml À1 IGF-1. Arterial preparations were maintained at 371C for 16 h. After incubation, the endothelium was removed and the tissue was placed in a bath of KHS at 371C with one end connected to a tissue holder and the other to a force -displacement transducer.
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Measurement of the expressions of the mRNAs for IGF-1 receptor, IGFBP-2, IGFBP-3, IGFBP-4, and IGFBP-5
Oligonucleotides The oligonucleotide primers for IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, which were designed from rat IGFBPs, are summarized in Table 1 .
RNA isolation and RT -PCR Reverse transcriptionpolymerase chain reaction (RT -PCR) was performed as previously described (Kobayashi & Kamata, 1999; Kobayashi et al., 2000; Kanie & Kamata, 2002) . RNA was isolated according to the guanidinium method. For the RT -PCR analysis, first-strand cDNA was synthesized from total RNA using oligo(dT)12 -18 and a cDNA Synthesis Kit (Life Sciences, Inc., FL, U.S.A.). RNA (1 mg) was reverse transcribed, and 28 PCR cycles (for the IGF-1 receptor and IGFBPs: 941C for 1 min, 581C for 1 min, 721C for 1 min) were performed in a final volume of 50 ml.
Following an analysis of reaction products at three-cycle increments to examine the linear phase of amplification, a total of 20 cycles was chosen for the quantitation of glyceraldehydes-3-phosphate dehydrogenase (GAPDH) and 28 cycles for both the IGF-1 receptor (Kobayashi & Kamata, 2002) and IGFBPs.
The PCR products obtained were analyzed on ethidium bromide-stained agarose (1.5%) gels. The obtained products and GAPDH products were quantified by scanning densitometry. The amounts of the IGF-1 receptor and IGFBPs were normalized with respect to the amount of GAPDH products.
Measurement of the expressions of IGF-1 receptor, IGFBP-4, and IGFBP-5 proteins by Western blotting
Aortas (three pooled vessels) were homogenized in ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, and protease-inhibitor cocktail.
Homogenates were centrifuged at 13,000 Â g for 5 min. The supernatant was sonicated at 41C and the proteins were solubilized in Laemmli's buffer containing mercaptoethanol. The protein concentration was determined by means of a BCA protein assay reagent kit (PIERCE, IL, U.S.A.). Samples (50 mg/lane) were resolved by electrophoresis on 10 or 15% SDS -PAGE gels and transferred onto PDVF membranes. Briefly, after blocking the residual protein sites on the membrane with Block ace (Dainippon-pharm., Osaka, Japan), the membrane was incubated with anti-IGF-1b-chain receptor (Santa Cruz, CA, U.S.A.), anti-IGFBP-4 antibody (1 : 1000), anti-IGFBP-5 (1 : 2000) in blocking solution. Horseradish peroxidase-conjugated, anti-rabbit antibody (Vector) was used at a 1 : 10,000 dilution in Tween PBS, followed by detection using SuperSignal (PIERCE).
Drugs
STZ, (À)NA hydrochloride, angiotensin II, insulin, and IGF-1 were all purchased from Sigma Chemical Co. (St Louis, MO, U.S.A.). ACh chloride was purchased from Daiichi Pharmaceuticals (Tokyo, Japan). Isotonic high K þ solution was prepared by replacing the NaCl with KCl. All drugs were dissolved in saline, except where otherwise noted. All concentrations are expressed as the final molar concentration of the base in the organ bath.
Statistical analysis
The contractile force developed by aortic strips from control and diabetic rats is expressed in mg tension mg tissue
À1
, the data being given as the mean7s.e.m. When appropriate, statistical differences were assessed using Dunnett's test for multiple comparisons after a one-way analysis of variance, a probability level of Po0.05 was regarded as significant. Statistical comparisons between concentration -response curves were assessed using a two-way ANOVA with a Bonferroni correction performed post hoc to correct for multiple comparisons; again, Po0.05 was considered significant.
Results
Plasma glucose, insulin, and cholesterol levels, and systolic blood pressure As indicated in Table 2 , plasma glucose levels were significantly elevated in STZ-induced diabetes (by comparison with the controls). Administration of insulin (30 U kg À1 day À1 for 2 weeks) in our established diabetic rats produced a glucose concentration that was not different from that of the controls. Plasma insulin levels, which were significantly lower in STZinduced diabetes than in the controls, were higher in both groups of insulin-treated animals than in the untreated diabetic rats. Plasma insulin levels were similar in insulin-treated controls and insulin-treated diabetic rats. Plasma total cholesterol and LDL cholesterol levels were significantly increased in STZ-induced diabetic rats, and while insulin administration significantly reduced the raised total cholesterol, it did not change the LDL level. Plasma triglyceride levels were significantly higher in the STZ-induced diabetic rats than in the controls, and administration of high-dose insulin to diabetic rats lowered the triglyceride level to that of the controls. Plasma HDL levels were similar among all the groups. Systolic blood pressure was significantly higher in the insulin-treated diabetics than in the untreated diabetics or insulin-treated controls (Table 2) . Contractile responses to NA, K þ , and angiotensin II Exposure of aortic strips to NA (10 À9 -10 À5 M) led to a concentration-dependent rise in tension in all the experimental groups. There were no significant differences, in terms of either maximum contractile force or sensitivity, between control and diabetic rats (Figure 1a ). Insulin treatment of our diabetic rats enhanced the aortic NA sensitivity to above that of the untreated diabetics and that of the controls ( Figure 1a and Table 3 ). Treating control rats with insulin had no significant effect on the contraction induced by NA (Figure 1a) . In aortic strips denuded of endothelium, (a) there was no significant difference, in terms of the maximum contractile response or sensitivity of aortic strips to NA, between control and diabetic rats, and (b) insulin treatment of our diabetic rats caused both an increase in the maximal response to NA and a substantial increase in the sensitivity to NA (as compared with untreated diabetics) ( Figure 1b and Table 2 ). Treating control rats with insulin had no significant effect on the contraction induced by NA in aortic strips without endothelium (Figure 1b) . Exposure of aortic strips to isotonic high K þ (10 -80 mM) or angiotensin II (10 À9 -10 À6 M) led to a concentration-dependent rise in tension in all the experimental groups, and there was no significant difference in sensitivity among the groups (Table 3) .
Contractile response to NA in aortas cultured with insulin or IGF-1
We used organ culture of the whole control or diabetic aortic wall because in this way it is possible to incubate the tissue with a constant concentration of insulin or IGF-1 for a long period of time, and both morphological and functional changes in the tissue can be easily examined. In aortas incubated in serum-free medium, NA induced a contraction of a magnitude similar to that induced by NA in fresh aortas. Incubating control aortas with insulin (500 ng ml À1 ) or IGF-1 (20 ng ml À1 ) had no significant effect on the contraction induced by NA in aortic strips denuded of endothelium ( Figure 2a and Table 4 ). In cultured aortas, we obtained the negative logarithm of the EC 50 for the contractile response to NA in both intact aortas and those denuded of endothelium. In diabetic aortas incubated with insulin (500 ng ml À1 , 16 h) or IGF-1 (20 and 50 ng ml
À1
, 16 h) this value was (a) significantly higher than those obtained for diabetic aortas incubated in serum-free medium, and (b) significantly higher than the . Aortic strips were taken from age-matched controls, untreated diabetic rats, insulin-treated controls, and insulin-treated diabetic rats. Ordinate shows increase in tension (expressed in mg tension mg tissue À1 ) measured at the peak of the response. Each data point represents the mean7s.e.m. of six to eight experiments; the s.e.m. is included only when it exceeds the dimension of the symbol used. *Po0.05, ***Po0.001 insulintreated control vs insulin-treated diabetic. (Figure 2b and Table 4 ). In contrast to the lack of effect of 20 ng ml À1 IGF-1 on control aortas (see above), incubating control aortas with high-dose IGF-1 (50 ng ml À1 ) in strips without endothelium gave a value that was significantly higher than that obtained for those incubated in serum-free medium (Figure 2a) . Incubating control and diabetic aortas for 16 h in modified KHS containing insulin (500 ng ml À1 ) or IGF-1 (20 ng ml À1 ) had no effect on the contraction caused by NA (Figure 3) . Exposure of aortic strips to isotonic high K þ (10 -80 mM) led to a concentration-dependent rise in tension in all experimental groups, and there was no significant difference in sensitivity among the IGF-1-treated groups (Table 4) .
Expressions of the mRNAs for IGF-1 receptor, IGFBP-2, IGFBP-3, IGFBP-4, and IGFBP-5
To investigate the possible mechanisms underlying the enhanced NA-induced contraction seen following ex vivo and in vivo insulin treatment in aortas from established diabetic rats, we examined whether the expressions of the mRNAs for the IGF-1 receptor and various IGFBPs might have been changed by the diabetes and the insulin treatment. Using RT -PCR on the total RNA isolated from the aortas of age-matched controls, untreated diabetic, and chronic Figure 2 Concentration -response curves for NA-induced contractions in endothelium-denuded strips of cultured aortas. Aortas from age-matched controls (a) and untreated diabetic (b) rats were cultured in serum-free medium or in the presence of insulin (500 ng ml À1 ) or IGF-1 (20 ng ml À1 , or 50 ng ml
À1
) for 16 h. Ordinate shows the increase in tension (expressed in mg tension mg tissue À1 ) measured at the peak of the response. Each data point represents the mean7s.e.m. of six to eight experiments; the s.e.m. is included only when it exceeds the dimension of the symbol used. *Po0.05, **Po0.01, ***Po0.001 diabetic aortas cultured with insulin vs diabetic aortas in serum-free medium. 
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insulin-treated control and diabetic rats, we found the following. The expression of GAPDH mRNA showed no differences among the four groups. The expression of the mRNA for the IGF-1 receptor was significantly increased in aortas from diabetic rats (vs controls), and further increased in those from high-dose insulin-treated diabetics, but it was not different between controls and insulin-treated controls (Figure 4 ). The expressions of the IGFBP-2 and IGFBP-3 mRNAs showed no differences among the various groups ( Figure 5 ). In contrast, by comparison with the expression levels in the controls, the expressions of the mRNAs for IGFBP-4 and IGFBP-5 were significantly decreased in aortas from insulin-treated and -untreated diabetic rats ( Figure 6 ).
Expressions of the proteins for IGF-1 receptor, IGFBP-4 and IGFBP-5
Western blotting was performed on aortas obtained from agematched controls, untreated diabetic, and chronic insulintreated control and diabetic rats. Use of the anti-IGF-1bR antibody allowed detection of immunoreactive proteins with molecular weights of 95 kDa (Figure 7a, left) . The expression of the IGF-1 receptor protein was increased in aortas from diabetic rats (vs controls), and further increased in those from high-dose insulin-treated diabetics, but it was not different between controls and insulin-treated controls (Figure 6a ). Use of anti-IGFBP-4 antibody or anti-IGFBP-5 allowed detection of immunoreactive proteins with molecular weights of 34 kDa (Figure 7a , right up) and 36 kDa (Figure 7a , right down), respectively. By comparison with the expression levels in the controls, the expressions of the IGFBP-4 or IGFBP-5 proteins were decreased in aortas from both insulintreated and -untreated diabetic rats (Figure 7b ). In aortas from both insulin-treated and -untreated diabetic rats, IGFBP-5 protein was not detected or quantified by scanning densitometry.
Discussion
The main conclusion we can draw from the present study is that in rats with established STZ-induced diabetes, insulin treatment led to an enhanced aortic NA sensitivity, although the same treatment did not have this effect in the age-matched Figure 3 Concentration -response curves for NA-induced contractions in endothelium-denuded aortic strips in modified KHS. Aortas from age-matched controls and untreated diabetic rats were incubated in KHS or in the presence of IGF-1 (20 ng/ml) for 16 h. Ordinate shows the increase in tension (expressed in mg tension mg tissue À1 ) measured at the peak of the response. Each data point represents the mean7s.e.m. of six to eight experiments; the s.e.m. is included only when it exceeds the dimension of the symbol used. ). **Po0.01, vs control.
w Po0.05, insulin-treated diabetic vs diabetic, ## Po0.01; insulin-treated diabetic vs insulintreated control.
290
T. Kobayashi et al
IGF-1 activities in established diabetes controls. Among organ-cultured rat aortas, the controls failed to show an enhanced NA sensitivity following incubation with IGF-1 or insulin, although such an effect was shown by diabetic aortas. In addition, in aortas from STZ-induced diabetic rats there were increases in IGF-1 receptor mRNA and protein, but decreases in IGFBP-4 and IGFBP-5 mRNAs and proteins. Hence, a likely mechanism for the enhancement of the NA-induced contraction seen in the insulin/IGF-1-treated diabetic aorta would involve an increase in IGF-1 receptors and decreases in some IGFBPs. This is the first report of such an effect of insulin in diabetes, and suggests a possible means by which the high levels of insulin in syndromes involving hyperinsulinemia may contribute to the progression of conditions such as hypertension. Administration of insulin to our established diabetic rats lowered their plasma glucose concentration to a level not different from that of the controls. Insulin administration to established diabetic rats also enhanced the aortic NA sensitivity to a value above those seen in the untreated diabetics and controls. The plasma insulin levels in the insulintreated rats were considerably higher than those of the untreated controls, suggesting the possibility that the insulininduced enhancement of the NA contractility in established diabetic rats may be due to an increase in the insulin concentration in the plasma. We have previously shown that in aortas from rats with established STZ-induced diabetes, insulin treatment enhances NA-induced contractility and blood pressure, but not isotonic K þ -induced contractility. In the same study, we demonstrated that this enhancement is related to an upregulation of the expression of the mRNA for the a 1B -or a 1D -adrenoceptor (Kobayashi & Kamata, 1999) .
In contrast, although treatment of control rats with insulin increased its plasma concentration, the NA-induced contractile response was not changed. Thus, insulin alone is not sufficient to cause an increase in the NA-induced contraction in the rat aorta. We have hypothesized elsewhere that the vasoactive effect of insulin in aortas from established diabetic rats may be distinct from that seen in control animals (Kobayashi & Kamata, 1999) . Recently, other studies have reported that an enhanced vasoactivity of both insulin and IGF-1 is associated directly with increased vascular contractility (Wu et al., 1994; Zhao et al., 2001) . Indeed, it has been reported that a chronic elevation of smooth muscle-targeted IGF-1 levels in transgenic mice enhances the contractility of the aorta (Zhao et al., 2001) . Furthermore, insulin and IGF-1 regulate the expression of the a 1D -adrenoceptor in rat vascular smooth muscle cells (Hu et al., 1996) , suggesting that the contractile effect of NA may be regulated in this way by insulin and IGF-1 in conditions involving hyperinsulinemia. In the present study, in organcultured diabetic aortas incubated for 16 h with insulin (500 ng ml À1 ) or IGF-1 (20 ng ml À1 ), the sensitivity of the contractile response to NA was significantly greater than that 
IGF-1 activities in established diabetes 291 seen in serum-free diabetic aortas, but incubating control aortas with insulin or IGF-1 under the same conditions had no such effect. In contrast, none of the aortas showed an enhanced contractility to isotonic high K þ . Hence, we have directly shown that treating aortas with insulin or IGF-1 enhances NA-induced vasocontractility only when the aortas are from diabetic rats, not when they are from control animals. On the other hand, studies on the effects of hyperinsulinemia show that the direct effects of insulin on vascular cells are weak, and that the principal response elicited by insulin is mediated through a crossreaction at high physiological insulin concentrations with the IGF-1 receptor (Wu et al., 1994; Zeng & Quon, 1996) . Indeed, the concentration of insulin needed to induce a given enhancement of biologic actions was about B100 times that of IGF-1 (Wu et al., 1994; Hu et al., 1996; Zeng & Quon, 1996) . In the present study, the concentrations of IGF-1 and insulin required to achieve the same effect were different by about 25-fold, suggesting that at least some of the vascular actions of insulin may be mediated through the IGF-1 receptor. Thus, the enhanced IGF-1-and insulin-responsiveness shown by diabetic but not control aortas may be related to the differences between control and diabetic rats in the IGF-1 receptors and IGFBPs in their vascular tissues.
The activities of IGF-1 in the circulation and in the tissues are regulated by the IGF-1 receptor and inhibited by various IGFBPs. We found in the present study that the expressions of IGF-1 receptor mRNA and proteins were increased, while both IGFBP-4 and IGFBP-5 mRNAs and proteins were decreased in aortas from diabetic rats (vs control rats). Rat aortas produce predominantly IGFBP-4, a known inhibitor of the action of IGF-1, together with smaller amounts of IGFBP-2 and IGFBP-3 (Kamyar et al., 1994; Wang et al., 1998) . IGFBP-5 enhances the actions of IGF-1 (Imai et al., 1997; Duan & Clemmons, 1998) . Probably, IGF-1 binding to the IGF-1 receptor is increased in the diabetic aorta as a result both of a reduced IGFBP-4 sequestration of IGF-1 and an increased IGF-1 receptor expression. As a consequence, insulin-treated or insulin/IGF-1-incubated diabetic aortas would be expected to show an enhanced NA-induced contraction. This raises the possibility that both exogenously added insulin and endogenous IGF-1 may upregulate the expression of the a 1 -adrenoceptor in the diabetic aorta via an action mediated by the increased IGF-1 receptors or the decrease in IGFBP-4 in vascular smooth muscle cells. As mentioned above, IGFBP-4 is the main IGFBP produced by rat aortic vascular smooth muscle cells (Kamyar et al., 1994; Wang et al., 1998) , and this IGFBP has been found consistently to antagonize the action of IGF-1 in vitro. In our study, both the mRNA and protein of IGFBP-4 were markedly decreased in aortas from diabetic rats, although it has been reported that diabetic rats have a normal serum level of IGFBP-4 and a only moderate decrease in the expression of its mRNA in the kidney (Price et al., 1997; Jehle et al., 1998) . Whether IGF and IGFBPs are involved in the vascular disease seen in macrovessels in diabetes has not been investigated in detail. However, it has been reported that forced overexpression of IGFBP-4 in the blood vessels of transgenic animals leads to smooth muscle cells showing hypoplasia as a result of an inhibition of the action of IGF-1 (Wang et al., 1998) . Recent studies have demonstrated that the secretion of IGFBP-4 and IGFBP-5 can be decreased by angiotensin II, thrombin, and transforming growth factor-b (TGF-b) (Anwar et al., 2000; Dahlfors & Arnqvist, 2000) . Thus, different growth factors and hormones, such as vascular endothelial growth factor, TGF-b, and angiotensin II, could play important role in the development of diabetic complications. The present data may suggest that established diabetes, by downregulating IGFBP-4 expression, leads to an increase in free IGF-1 or insulin, which are thus available for stimulation of the relevant receptors.
To our surprise, high-concentration insulin treatment given to established diabetic rats failed to normalize the expression of the IGF-1 receptor or IGFBP-4 in the aorta. On the contrary, the expression of the IGF-1 receptor was further increased in insulintreated diabetics. These results suggest that high-concentration insulin treatment in established diabetes would not ameliorate existing changes in the IGF system (and may even further enhance the action of IGF-1 in the aorta). Thus, changing the plasma insulin in vivo may not necessarily have beneficial effects in terms of IGF-1-receptor and IGFBP expressions.
In general, NA is released from sympathetic neurons together with ATP or neuropeptide Y (NPY). However, we did not examine changes in the responses to ATP or NPY in the present study. Since the receptors for these agonists might be changed in diabetic-and insulin-treated diabetic rats, we shall need to conduct further studies to examine the effects of ATP and NPY in such rats, focusing on the hypertension seen in insulin-treated diabetic rats.
In conclusion, we have shown that in the aorta in rats with established STZ-induced diabetes, insulin treatment can enhance NA-induced contractility (and presumably blood pressure). The above effects may be made possible as a result of the increase in IGF-1 receptors and the decreased IGFBPs expressions that occur in the aorta in long-term insulin deficiency. Furthermore, the expression of the IGF-1 receptor was higher in the aorta in insulin-treated diabetic rats than in either untreated diabetic or insulin-treated control rats. The downside is that such a perturbation of the activity in the IGF-1 system in diabetes could be a key event in the progress of arteriosclerosis and hypertension in syndromes involving hyperinsulinemia.
